Abstract
Osteoarthritis (OA) of the knee causes disability, pain, and progressive destruction of cartilage in adult women. The objective of the study was to evaluate the concentrations of the urinary biomarker C-terminal telopeptide of type II collagen (CTX-II) and pain by radiographic grade in women with knee OA in northeastern Mexico: Cross-sectional study of 155 women with knee OA. Concentrations of biochemical parameters were evaluated and urine samples were collected to measure biomarker levels (uCTX-II) ng/mmol by competitive enzyme-linked immunoabsorbent assay (ELISA) technique and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale was used for pain classification; median age of 49 years and 29.1 kg/m2 of body mass index (BMI). uCTX-II biomarker levels were grade 2 (210.7 ng/mmol), grade 3 (314.8 ng/mmol), and grade 4 (478.8 ng/mmol) relative to Kellgren and Lawrence, uCTX-II levels were compared with WOMAC scale and presented significant statistical difference (p = 0.0001). An association of the biomarker CTX-II and an increase in BMI was found in female patients with knee OA (odds ratio = 1.01; 95% confidence interval 1.001–1.005; p = 0.047).This study demonstrates an increase in the levels of the biomarker uCTX-II, the degree of pain, and radiographic grade in women with knee OA in northeastern Mexico.
Highlights
Osteoarthritis (OA) is the most prevalent joint disease causing appreciable disability in most adults >55 years of age.[1,2] The knee is the most affected joint,[3] manifested with pain, stiffness, and considerable functional disability,[4] especially in women.[5,6] Recent studies have revealed that, compared with healthy women, women with OA of the knee have decreased survival rates.[7]
A discordance between symptoms and structure has been widely observed in OA, based on observations of weak correlations between radiographic severity and pain; the determination of some biomarkers may be very useful in clinical practice as a diagnostic procedure or prognosis of degenerative disease, this study aims to evaluate the concentrations of urinary CTX-II biomarker, pain, and radiographic grade in Mestizo women with knee OA in northeastern Mexico
The WOMAC scale score was used to assess the symptomatology mainly to measure the pain perceived by patients with OA of the knee by means of a personal interview, which found that 23.8% of the patients had no knee pain, 50.3% had pain 15 days per month
Summary
Osteoarthritis (OA) is the most prevalent joint disease causing appreciable disability in most adults >55 years of age.[1,2] The knee is the most affected joint,[3] manifested with pain, stiffness, and considerable functional disability,[4] especially in women.[5,6] Recent studies have revealed that, compared with healthy women, women with OA of the knee have decreased survival rates.[7] The incidence increases with age.[8] OA patients with increased body mass index (BMI) show an increased risk of comorbidities.[9,10] The diagnosis of the disease is usually based on clinical symptoms and radiographic changes; X-ray images are the gold standard to confirm the clinical diagnosis and grade of disease.[11,12] In contrast, the determination of biomarkers in OA is very useful to evaluate joint injury, one of the biomarkers most studied to determine the severity and degradation of cartilage in OA of the knee is the C-terminal telopeptide of type II collagen (CTX-II), which has been used as a marker of progression of cartilaginous injuries a Francisco Javier Garcıa-Alvarado et al 2020; Published by Mary Ann Liebert, Inc. Osteoarthritis (OA) is the most prevalent joint disease causing appreciable disability in most adults >55 years of age.[1,2] The knee is the most affected joint,[3] manifested with pain, stiffness, and considerable functional disability,[4] especially in women.[5,6] Recent studies have revealed that, compared with healthy women, women with OA of the knee have decreased survival rates.[7] The incidence increases with age.[8] OA patients with increased body mass index (BMI) show an increased risk of comorbidities.[9,10] The diagnosis of the disease is usually based on clinical symptoms and radiographic changes; X-ray images are the gold standard to confirm the clinical diagnosis and grade of disease.[11,12] In contrast, the determination of biomarkers in OA is very useful to evaluate joint injury, one of the biomarkers most studied to determine the severity and degradation of cartilage in OA of the knee is the C-terminal telopeptide of type II collagen (CTX-II), which has been used as a marker of progression of cartilaginous injuries a Francisco Javier Garcıa-Alvarado et al 2020; Published by Mary Ann Liebert, Inc
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call